A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer

About 20 percent of TNM-stage II colon cancer patients who are treated by surgical resection develop recurrence, and adjuvant chemotherapy in this group is still debated among researchers and clinicians. Currently, adverse histopathological and clinical factors are used to select patients for adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob, Havjin, Stanisavljevic, Luka, Storli, Kristian Eeg, Hestetun, Kjersti E., Dahl, Olav, Myklebust, Mette P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906690/
https://www.ncbi.nlm.nih.gov/pubmed/29670141
http://dx.doi.org/10.1038/s41598-018-24519-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906690/
https://www.ncbi.nlm.nih.gov/pubmed/29670141
http://dx.doi.org/10.1038/s41598-018-24519-4

Ejemplares similares